ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2201

Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders

Alhanouf Alsaleem1, Lujain Akbar2 and Sulaiman Al-Mayouf3, 1KFSH&RC, Riyadh, Saudi Arabia, 2RIYADH, RIYADH, Saudi Arabia, 3KFSHRRC, Riyadh, Saudi Arabia

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, genetics, immunology, Inflammasome, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Human inborn errors of immunity are caused by monogenic germline mutations characterized by Immunodeficiency like features with increase susceptibility to infection as well as concomitant diversity of autoimmune, autoinflammatory manifestations. We aim to describe the phenotype and genotype features of patients with genetically confirmed autoinflammatory disease (AID) associated with immunodeficiency.

Methods: Data of 22 patients with confirmed monogenic AID and immunodeficiency features were retrospectively collected. Medical records were reviewed for demographic, family history, clinical and genetic data. Sequencing analysis was done in all included patients.

Results: Out of 125 patients with AID, 22 patients (13 female) have been evaluated since 2005. Median age of disease onset 17 months (IQR: 6-36) and median age of diagnosis 4.5 years (IQR: 3-8.5). Parental consanguinity rate was (77%). Patients had variations in the following genes: RNF31, OTULIN, WDR1, ISG15, STAT1, TNFAIP3, SOCS1, NLRP12, ADA2, ILRA17, ZNFX1, STING, IFIH1, DNASE2. Among the 17 detected variants, (61%) identified as novel. Notably, genetic variations associated with type I Interferon and NF-KB pathways were the most frequent AID. The main clinical features were fever (100%), cutaneous (72%), gastrointestinal (68%), neurology (63%), MSK (59%), and pulmonary (45%). Immunodeficiency features included recurrent infections (68%) mostly viral, hypogammaglobinemia (77%), and abnormal lymphocyte markers (63%). Two patients had mycobacterial infection. Immunoglobulin therapy and prophylactic antibiotics were frequently administered. More than half of the patients required steroids and immunomodulatory agents. BMT done in 1 patient. The mean accrual damage was 6.6+3.4. There were 2 deaths reported secondary to infections.

Conclusion: Immunodeficiency manifestations are frequently detected in interferon and NF-KB monogenic AID. The concomitant use of immunoglobulin and prophylactic antimicrobial with immunosuppressive therapy played a fundamental balance. We have identified rare and novel genetic variants which probably contributed to the increased incidence of immunodeficiency in AID.  


Disclosures: A. Alsaleem: None; L. Akbar: None; S. Al-Mayouf: None.

To cite this abstract in AMA style:

Alsaleem A, Akbar L, Al-Mayouf S. Immunodeficiency-Related Monogenic Autoinflammatory Diseases; Expanding Spectrum of Immunodysregulation Disorders [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/immunodeficiency-related-monogenic-autoinflammatory-diseases-expanding-spectrum-of-immunodysregulation-disorders/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/immunodeficiency-related-monogenic-autoinflammatory-diseases-expanding-spectrum-of-immunodysregulation-disorders/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology